Journal: Frontiers in Immunology
Article Title: A novel hypoxia- and lactate metabolism-related prognostic signature to characterize the immune landscape and predict immunotherapy response in osteosarcoma
doi: 10.3389/fimmu.2024.1467052
Figure Lengend Snippet: Expression and biological functions on growth of SFXN4 and SQOR in osteosarcoma. (A) SFXN4 and SQOR expression in para-cancerous and osteosarcoma tissues by IHC. (B, C) The expression of SFXN4 and SQOR at RNA and protein levels in normal osteoblast cell and osteosarcoma cell lines through qRT-PCR and western blotting assays. (D, E) Effect of knocking down SFXN4 and SQOR at RNA and protein levels in osteosarcoma cell lines by qRT-PCR and western blotting assays. (F, G) CCK8 and colony formation assays demonstrating the proliferation capacity ability after knocking down SFXN4 and SQOR in osteosarcoma cell lines. ∗ p < 0.05, ∗∗ p < 0.01.
Article Snippet: Human osteosarcoma cell lines (HOS, 143B) and human normal osteoblast cell lines (hFOB1.19) were purchased from Procell Life Science and Technology Co., Ltd. (Wuhan, China).
Techniques: Expressing, Quantitative RT-PCR, Western Blot